Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Perrysburg, Ohio, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The firm is closely monitoring whether these drugs will surpass fourth-quarter consensus ... is seen as favorable for Eli Lilly, whose tirzepatide demonstrated a 20.9% weight loss.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Medscape News Slideshows, August 16, 2021 Questions Remain as More 'Twincretin' Data in Diabetes Published As another phase 3 trial of tirzepatide, SURPASS-3, is published, an accompanying ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Mounjaro along with Zepbound -- both of which are the exact same molecular formula, called tirzepatide -- are still ... got the least distance to travel to surpass Berkshire's size.